Ipamorelin vs hgh: how the two actually compare

Last updated 2026-07-24

What's the basic difference between ipamorelin and HGH?

HGH, also called somatropin, is recombinant human growth hormone itself. When you inject it, you're putting the actual hormone into your bloodstream, and your pituitary gland has nothing to do with it. Ipamorelin is a different animal entirely: it's a small peptide that mimics ghrelin and binds to the growth hormone secretagogue receptor (GHS-R1a), which tells your own pituitary to release GH that's already sitting there in storage. The original 1998 paper describing ipamorelin called it "the first selective growth hormone secretagogue," meaning it stimulates GH release without meaningfully touching cortisol, prolactin, or other pituitary hormones the way some earlier peptides did ^[1]. That selectivity is the whole reason ipamorelin got attention in the first place. Earlier GH-releasing peptides (GHRP-6, GHRP-2, hexarelin) also bump cortisol and prolactin as a side effect. Ipamorelin, at least in the original pharmacology work, mostly doesn't. So the practical distinction is: HGH replaces the hormone. Ipamorelin asks your pituitary to make more of it, and only works if your pituitary is still capable of responding. That second point matters a lot for older adults or anyone with actual pituitary damage, which we'll get to below. A 2026 review in the International Journal of Molecular Sciences groups ipamorelin among therapeutic peptides used across metabolic and endocrine conditions, distinct from hormone-replacement approaches like direct HGH administration ^[2]. The mechanisms aren't just academically different, they lead to different clinical use cases.

How does each one work in the body, mechanistically?

Ipamorelin's mechanism runs through the ghrelin receptor pathway. A 1998 medicinal chemistry paper described it as part of a new series of orally-inspired growth hormone secretagogues built around that receptor target ^[3], and a companion paper the same year detailed a series of potent GH-releasing peptides derived directly from the ipamorelin scaffold ^[4]. The peptide binds GHS-R1a on somatotroph cells in the pituitary, which triggers calcium signaling and a burst of stored GH release. This is pulsatile by nature, meaning it mimics the body's normal rhythm of GH secretion rather than creating a flat, constant elevation. HGH given as a drug skips all of that. It's the finished hormone, delivered directly to peripheral tissue and to the liver, where it drives IGF-1 production. There's no receptor-binding step at the pituitary because the pituitary isn't involved at all. This distinction shows up in the animal literature too. A 1999 study found ipamorelin induces longitudinal bone growth in rats through this GH-releasing mechanism ^[5], and a 2001 paper in Growth Hormone & IGF Research showed ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats ^[6], again by prompting endogenous GH release rather than supplying exogenous hormone. A related 2000 study found ipamorelin combined with GHRP-6 increased bone mineral content in adult female rats ^[7]. These are animal, not human clinical, endpoints, and they don't establish a bone benefit in people. But they map onto the mechanism cleanly: pulsatile endogenous release, not replacement. One more mechanistic wrinkle: a 2001 paper in Biochemical and Biophysical Research Communications found that GH secretagogues can stimulate adiposity through a GH-independent pathway ^[8], meaning some downstream effects of secretagogues like ipamorelin may not run entirely through the GH-IGF-1 axis. That's a reminder that "it stimulates GH" isn't the whole mechanistic story, even in animal models.

Which one is FDA-approved, and does that matter?

HGH (somatropin) is an FDA-approved drug, listed under multiple approved brand names in the Drugs@FDA database, with defined indications like growth hormone deficiency and certain wasting conditions ^[9]. Ipamorelin is not an FDA-approved drug. It has never gone through a new drug application for a general clinical indication. That matters practically. Ipamorelin is available through compounding pharmacies operating under section 503A or 503B of the Food, Drug, and Cosmetic Act, which governs pharmacy compounding using bulk drug substances ^[10]. Whether a given peptide is legally compoundable depends on its status on FDA's 503A and 503B bulk drug substance lists, which the agency maintains and updates ^[11][12]. The regulation itself defines compounding around whether a substance appears on those lists and whether it's being compounded for an individual patient with a valid prescription ^[10]. HGH's approval status also means dosing, purity standards, and manufacturing are locked down by FDA review. Ipamorelin, dispensed through compounding, doesn't go through that same premarket review process. That's not automatically disqualifying (compounding is legal and common for many drugs), but it's a real difference in regulatory footing that's worth understanding before you compare the two on any other axis.

How do ipamorelin and HGH compare on GH and IGF-1 output?

This is where the honest answer is: the human comparative data is thinner than marketing copy suggests. A 1999 pharmacokinetic-pharmacodynamic modeling study in Pharmaceutical Research characterized how ipamorelin behaves in human volunteers, describing the dose-response relationship for GH release following ipamorelin administration ^[13]. That's real human PK/PD data, but it's a modeling study of GH pulses after ipamorelin dosing, not a head-to-head trial against injected HGH measuring downstream IGF-1 over weeks or months. HGH, by contrast, has decades of dose-response data behind its approved indications, because that's what an FDA approval requires. The two data sets aren't comparable in depth, and no rigorous randomized trial in the cited pack directly pits ipamorelin against HGH on IGF-1 outcomes in humans.

Does ipamorelin actually build muscle or burn fat the way HGH does?

Some of the loudest claims about ipamorelin (dramatic fat loss, fast muscle gain) come from bodybuilding forums, not from the peptide literature. That distinction matters and we want to be clear about it here: what follows is what's actually been studied, not folklore. A 2020 review in Translational Andrology and Urology looked at growth hormone secretagogues in the context of managing body composition in hypogonadal men, discussing secretagogues as a class alongside androgen-focused approaches ^[14]. That's a narrower and more cautious claim than "ipamorelin burns fat," and it's specific to a hypogonadal population, not general fitness use. A 2009 study in Growth Hormone & IGF Research examined GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats, a proxy for protein-sparing and anti-catabolic effects ^[15]. Again: rats, and a metabolic proxy, not a human muscle-mass trial. The honest summary: there's real mechanistic and animal-model support for ipamorelin doing GH-secretagogue things (releasing GH, affecting bone density markers, influencing nitrogen balance), but there isn't a solid human RCT in this evidence base showing ipamorelin produces HGH-equivalent muscle or fat outcomes in healthy adults. If someone is promising you HGH-like body recomposition from ipamorelin with a citation to a forum thread, that's not the same thing as a citation to a journal.

What about non-bodybuilding medical uses, like gut motility or pain?

This is actually where ipamorelin has some of its more interesting, though narrow, human data. A 2014 randomized, controlled proof-of-concept study published in the International Journal of Colorectal Disease tested ipamorelin for managing postoperative ileus in bowel resection patients ^[16]. That's a real human RCT, in a specific surgical population, for a specific GI motility endpoint, not a general wellness or anti-aging claim. Supporting rodent work backs this up mechanistically: a 2009 study in the Journal of Pharmacology and Experimental Therapeutics found ipamorelin was effective against gastric dysmotility in a rodent model of postoperative ileus ^[17], and a related 2012 paper in the Journal of Experimental Pharmacology confirmed efficacy on gastric dysmotility in the same rodent ileus model ^[18]. There's also a pain angle. A 2020 paper in the Journal of Experimental Pharmacology examined ghrelin mimetics, including ipamorelin, for attenuation of visceral and somatic nociception ^[19]. And a 2024 study in Physiology & Behavior found that ipamorelin, along with the related compound anamorelin, inhibited cisplatin-induced weight loss in ferrets, with anamorelin additionally showing anti-emetic effects through a central mechanism ^[20]. None of this is about muscle or bodybuilding. It's about GI surgery recovery, cancer-related cachexia and nausea, and pain signaling, which tells you the serious clinical interest in ipamorelin has mostly run through gastroenterology and supportive oncology, not fitness.

Is ipamorelin safer than HGH, or just less studied?

"Safer" isn't quite the right frame. Ipamorelin's original characterization as a selective secretagogue suggested a cleaner side-effect profile relative to older, less selective GH-releasing peptides, specifically less cortisol and prolactin stimulation ^[1]. That's a real, specific finding, not a blanket safety claim. But HGH has a much longer track record precisely because it's an approved drug with mandatory post-market surveillance. Its known risks (edema, joint pain, insulin resistance at high doses, and in some populations increased cancer risk concerns that FDA-approval review processes weigh) are documented through that formal approval pathway. Ipamorelin, compounded rather than FDA-approved, doesn't have that same scale of long-term human safety surveillance behind it. A 2018 study in Growth Hormone & IGF Research analyzed new growth-promoting products showing up on the black market, a reminder that peptides sold outside legitimate pharmacy channels carry contamination and mislabeling risks that have nothing to do with the molecule's own pharmacology [16, ref 17 in original numbering]. That's an argument for sourcing through a legitimate, provider-reviewed pharmacy channel rather than gray-market vendors, regardless of which GH-axis product you're considering. If you want the fuller safety rundown specific to ipamorelin, see ipamorelin side effects. A 2004 study in Neuroendocrinology Letters looked at ipamorelin's effect on insulin release from the pancreas in normal and diabetic rats ^[21], which is worth knowing if you have any glucose-handling concerns, since GH-axis stimulation broadly (whether from HGH or a secretagogue) can affect insulin sensitivity.

How is ipamorelin actually dosed, and is it ever sold alone?

This is a point worth being direct about. There is no standalone ipamorelin product on the market. Ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend through compounding pharmacies, not as an isolated SKU. Tesamorelin is itself an FDA-approved GHRH analog for a specific indication (HIV-associated lipodystrophy), and pairing it with ipamorelin in a compounded blend is a common formulation approach, but that's a compounding decision, not evidence that the combination has been studied as a unit in large trials. Dosing protocols you'll see online, often expressed as fixed microgram amounts per injection, mostly trace back to practitioner experience and compounding pharmacy guidance rather than to a published human dose-ranging trial specifically for the blended product. The 1999 human PK/PD modeling paper on ipamorelin gives some grounding for dose-response expectations for ipamorelin itself ^[13], but that's for the peptide alone, in a research setting, not the marketed blend. If you're trying to figure out actual injection volumes, reconstitution ratios, and typical starting doses, our ipamorelin dosage page and the cjc-1295 ipamorelin dosage calculator walk through the math. And if you're staring at a vial and a vial of bacteriostatic water wondering what to do next, reconstitute cjc ipamorelin covers the practical steps.

How is HGH dosed, and how does that compare to a secretagogue like ipamorelin?

HGH dosing, because it's an approved drug, is defined by FDA-reviewed labeling for each specific indication, typically weight-based or in defined milligram ranges depending on the condition being treated, and it requires a prescription tied to a diagnosed condition like documented growth hormone deficiency. You can look up specific approved HGH products and their labeled dosing directly in the Drugs@FDA database ^[9]. Ipamorelin dosing, since there's no FDA-approved label, comes from compounding pharmacy protocols and the research literature rather than an approved package insert. That's a meaningfully different level of dosing certainty. With HGH, the dose-response relationship for the approved indication has been through formal review. With ipamorelin, you're relying on smaller studies, like the 1999 PK/PD paper ^[13], plus clinical judgment from the prescribing and compounding pharmacy. This is also part of why ipamorelin protocols tend to emphasize small, frequent doses (mimicking natural pulsatile GH release) rather than the flatter, less frequent dosing schedule typical of injected HGH. The mechanisms genuinely call for different administration patterns, it's more than a marketing difference.

What does peptide metabolism tell us about how each is absorbed and cleared?

Ipamorelin, like most peptides, gets broken down by peptidases in the blood and tissue relatively quickly. A 2012 analytical chemistry study specifically characterized the metabolism of growth hormone releasing peptides, mapping out breakdown products ^[22]. A 2015 study in Drug Testing and Analysis went further, identifying specific ipamorelin metabolites in human urine after nasal administration, alongside metabolites of GHRP-1, GHRP-2, GHRP-6, and hexarelin ^[23]. That work exists partly because anti-doping labs need to detect these peptides, which tells you something about where the serious analytical chemistry interest in ipamorelin has come from: sports anti-doping testing, not consumer marketing. A 1998 pharmacokinetic evaluation specifically looked at nasal absorption of ipamorelin and related peptidyl secretagogues ^[12], relevant if you've seen nasal-spray GH secretagogue products marketed anywhere; the absorption profile via that route is measurably different from subcutaneous injection. HGH's metabolism, being the native hormone, follows the body's own well-characterized clearance pathways for growth hormone, which is one more reason its dosing and half-life data are so much more solidly established in humans than ipamorelin's.

Is one more likely to show up on a doping test than the other?

Both can. HGH doping detection is well established in elite sport, with dedicated isoform and biomarker tests that anti-doping labs have used for years. Ipamorelin and related GH-releasing peptides are also detectable; that's precisely what the 2015 Drug Testing and Analysis metabolite study was built to support, characterizing ipamorelin metabolites in human urine specifically for detection purposes after nasal dosing ^[23]. A 2017 paper in the same journal laid out structure-activity relationships across peptidic GH secretagogues, again largely in service of building better detection assays ^[24]. If you're competing under any drug-tested federation, treat both HGH and ipamorelin as detectable performance-enhancing substances, not as some kind of loophole around GH testing. Recent sports-medicine literature has taken this seriously too: a 2026 JBJS Reviews paper reviewed injectable peptides in sports medicine specifically through an antidoping lens ^[25], and a companion 2026 review in The American Journal of Sports Medicine framed injectable peptide therapy, including secretagogues, as a topic orthopedic and sports medicine physicians need a working primer on ^[26]. A 2026 Sports Medicine review went further, specifically evaluating the safety and efficacy of both approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance, treating that regulatory distinction as central to the clinical picture ^[27].

Where does ipamorelin fit in orthopedic and musculoskeletal medicine specifically?

This is a newer and more clinically grounded thread than the bodybuilding conversation. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked specifically at therapeutic peptides in orthopedics, covering applications, challenges, and future directions across the field ^[28]. Growth hormone secretagogues, ipamorelin included, get discussed there in the context of bone and soft-tissue healing potential, building on the older rodent bone-density work ^[5][6][7], not as a fat-loss or muscle shortcut. A 2026 review in Frontiers in Aging looked at therapeutic peptides in gerontology, discussing mechanisms and applications relevant to healthy aging broadly [6, cross-ref], which is a more measured framing than a general wellness pitch, and worth reading if that's the angle that brought you to ipamorelin in the first place. The throughline across this newer clinical literature is caution: these are early-stage reviews of an emerging area, not confirmations that ipamorelin is a proven orthopedic treatment. Treat 2026 review-of-the-field papers as "here's what's being studied and why it's interesting," not as "this is now standard of care."

So which one should you actually consider, ipamorelin or HGH?

If you have a diagnosed condition with an FDA-approved indication for HGH, that's a conversation for your prescribing physician using an approved drug with a real label. That's not what this article is meant to substitute for. If you're exploring GH secretagogues for off-label goals like body composition or recovery support, the honest picture is: ipamorelin has real, selective pharmacology behind it ^[1], real animal data on bone and metabolic effects ^[5][6][7], a couple of genuinely interesting human RCTs in narrow surgical contexts ^[16], and essentially zero large human trials proving the broader claims that circulate in fitness spaces. It is not FDA-approved, it is not sold as a standalone product, and any legitimate access to it runs through a licensed provider and a compounding pharmacy working from a valid prescription, dispensed as part of a tesamorelin/ipamorelin blend, not as ipamorelin alone. At Ipamorelin Co, our role is connecting people to that kind of provider-reviewed pathway rather than a gray-market vial. If you're at the point of actually weighing options, buy ipamorelin walks through what a legitimate, provider-reviewed path to a compounded tesamorelin/ipamorelin blend actually looks like, including what a fulfilling pharmacy partner does and doesn't do in that chain. Start with ipamorelin if you want the fuller mechanism and evidence rundown before you get anywhere near a dosing decision.

Frequently asked questions

Is ipamorelin the same thing as HGH?

No. HGH is the growth hormone itself, injected directly. Ipamorelin is a peptide that binds the ghrelin receptor (GHS-R1a) and prompts your own pituitary to release its own stored GH ^[1]. Ipamorelin only works if your pituitary can still respond; HGH bypasses the pituitary entirely.

Can you buy ipamorelin by itself, without anything else in it?

No. There's no standalone ipamorelin product on the market. It's dispensed through compounding pharmacies as part of a tesamorelin/ipamorelin blend. Anyone offering pure isolated ipamorelin as a retail product outside a compounding-pharmacy, prescription-based channel is operating outside the normal legitimate supply chain.

Is ipamorelin FDA-approved like HGH is?

No. HGH (somatropin) is FDA-approved with indications listed in the Drugs@FDA database ^[13]. Ipamorelin has no FDA approval; it's available only through compounding pharmacies operating under section 503A or 503B rules governing bulk drug substances ^[16][17].

Does ipamorelin raise IGF-1 the same way HGH does?

Ipamorelin stimulates a pulse of endogenous GH release, which can raise IGF-1 indirectly, but there's no head-to-head human trial in the current literature comparing ipamorelin's IGF-1 effect against injected HGH over time. A 1999 human PK/PD study modeled ipamorelin's GH-release dose-response ^[12], but that's not a long-term IGF-1 comparison.

Why does ipamorelin need a working pituitary but HGH doesn't?

Ipamorelin works by binding GHS-R1a receptors on pituitary somatotroph cells, triggering release of GH that's already stored there ^[1]. If the pituitary is damaged or non-functional, there's nothing for ipamorelin to stimulate. HGH is the finished hormone delivered directly, so it doesn't depend on pituitary function at all.

Is ipamorelin safer than HGH?

Ipamorelin's original 1998 characterization found it was more selective than older GH-releasing peptides, meaning less cortisol and prolactin stimulation ^[1]. But HGH has far more long-term human safety data because it's gone through FDA approval and post-market surveillance; ipamorelin, as a compounded product, hasn't.

What does the human research actually show ipamorelin does?

The clearest human data is a 2014 randomized controlled trial showing ipamorelin helped manage postoperative ileus after bowel resection surgery ^[15]. Beyond that, most of the supporting evidence is rodent studies on bone density, nitrogen balance, and gastric motility, plus one 1999 human PK/PD modeling paper ^[12]. Body-composition claims common online aren't backed by large human RCTs in this evidence base.

Does ipamorelin help with fat loss or muscle gain like HGH is claimed to?

There's no strong human RCT in the current literature directly showing ipamorelin produces HGH-equivalent fat loss or muscle gain in healthy adults. A 2020 review discussed GH secretagogues for body composition specifically in hypogonadal men ^[5], a narrower claim than general fitness marketing suggests.

Will ipamorelin or HGH show up on a drug test?

Both can be detected. Anti-doping labs have developed specific metabolite-detection methods for ipamorelin and related GH-releasing peptides ^[23][24], and HGH has established isoform-based detection methods in elite sport. Treat both as detectable performance-enhancing substances under any drug-tested federation.

How is ipamorelin dosed compared to HGH?

HGH dosing follows FDA-reviewed labeling, typically defined milligram amounts tied to a specific approved indication ^[13]. Ipamorelin dosing comes from compounding pharmacy protocols and smaller research studies rather than an approved label, often given as small, frequent doses to mimic natural pulsatile GH release.

Is ipamorelin used for anything besides bodybuilding-style goals?

Yes, and this is where its most solid human evidence sits. A 2014 RCT tested it for postoperative ileus after bowel surgery ^[15], and separate research has looked at ghrelin mimetics like ipamorelin for pain signaling ^[8] and for countering cisplatin-induced weight loss in animal models ^[7].

What's the difference between ipamorelin and tesamorelin?

Tesamorelin is a GHRH analog, FDA-approved for HIV-associated lipodystrophy, that acts on a different pituitary receptor than ipamorelin's ghrelin-receptor mechanism. Because they hit different receptors, they're often compounded together; that's why ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend rather than as a standalone product.

Where does ipamorelin come from if it's not FDA-approved?

Legitimate ipamorelin comes from compounding pharmacies working under 503A or 503B rules, which govern which bulk substances pharmacies can legally compound and dispense with a valid prescription ^[16][17]. Buying it outside that channel, from unregulated online sellers, carries real contamination and mislabeling risk, as documented in a 2018 analysis of black-market growth-promoting products [16-black-market-ref].

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin was characterized as the first selective growth hormone secretagogue, with minimal cortisol/prolactin stimulation compared to earlier GH-releasing peptides
2. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): A 2026 review covers therapeutic peptides in orthopedics, including applications and challenges relevant to bone and soft-tissue healing
3. The American Journal of Sports Medicine, 2026 (PMID 41476424): A 2026 primer for orthopedic and sports medicine physicians covers injectable peptide therapy including GH secretagogues
4. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): A 2026 review evaluates safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injury and athletic performance
5. Translational Andrology and Urology, 2020 (PMID 32257855): GH secretagogues are discussed as a body-composition management option specifically in hypogonadal men
6. International Journal of Molecular Sciences, 2026 (PMID 42123471): A 2026 review groups ipamorelin among therapeutic peptides used in aesthetic, metabolic, and endocrine conditions
7. Physiology & Behavior, 2024 (PMID 39043357): Ipamorelin and anamorelin inhibited cisplatin-induced weight loss in ferrets, with anamorelin also showing central anti-emetic effects
8. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics including ipamorelin were studied for attenuation of visceral and somatic nociception
9. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes novel orally active growth hormone secretagogues built around the ghrelin receptor pathway
10. Analytical Chemistry, 2012 (PMID 23101768): Characterizes the metabolism and breakdown products of growth hormone releasing peptides including ipamorelin
11. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in rats via GH-releasing mechanism
12. Pharmaceutical Research, 1999 (PMID 10496658): Human PK/PD modeling study characterized the dose-response of GH release following ipamorelin administration in volunteers
13. Drugs@FDA, FDA-approved drug products database: HGH (somatropin) products are FDA-approved with defined labeled indications, unlike ipamorelin
14. Growth Hormone & IGF Research, 2009 (PMID 19231263): Examined GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats
15. International Journal of Colorectal Disease, 2014 (PMID 25331030): Randomized controlled proof-of-concept trial found ipamorelin useful for managing postoperative ileus in bowel resection patients
16. 21 U.S.C. 353a, pharmacy compounding: Defines the legal framework under which pharmacies may compound drugs like ipamorelin for individual patients with a prescription
17. FDA, bulk drug substances used in compounding under section 503A: FDA maintains the list determining which bulk substances, including peptides like ipamorelin, may legally be compounded under 503A
18. Xenobiotica, 1998 (PMID 9879640): Evaluated pharmacokinetics of ipamorelin and related peptidyl GH secretagogues with emphasis on nasal absorption
19. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Confirmed ipamorelin efficacy on gastric dysmotility in a rodent model of postoperative ileus
20. The Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Demonstrated ipamorelin efficacy in a rodent model of postoperative ileus
21. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats
22. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Described a new series of highly potent growth hormone-releasing peptides derived from ipamorelin
23. Drug Testing and Analysis, 2015 (PMID 25869809): Identified specific ipamorelin metabolites in human urine after nasal administration, developed for anti-doping detection
24. Drug Testing and Analysis, 2017 (PMID 26811125): Laid out structure-activity relationships across peptidic GH secretagogues to support detection assay development
25. The Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin combined with GHRP-6 increased bone mineral content in adult female rats
26. Neuro Endocrinology Letters, 2004 (PMID 15665799): Examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats
27. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): Found GH secretagogues can stimulate adiposity through a GH-independent mechanism
28. JBJS Reviews, 2026 (PMID 42160466): Reviewed injectable peptides in sports medicine specifically through an antidoping and safety lens